Spring 2018

Helping Women in Recovery

Creating better animal models may help pregnant women—and support children exposed to opioids in utero.

By Genevieve Rajewski

The number of babies born exposed to opiates in the United States increased fivefold between 2000 and 2012, according to the latest available data from the National Institutes of Health. Within hours or days after birth, these infants may experience opioid withdrawal, leading to significant weight loss and seizures. But few studies have effectively considered the effects of in utero opioid exposure—either from illegal drugs or from those prescribed as part of addiction treatment—on children’s physical, mental and social development. This leaves clinicians facing a difficult challenge: How best to meet the health and recovery needs of a pregnant women, while ensuring the health of their babies?

“We can’t afford to wait until all these kids hit first grade, middle school, and adulthood to learn what the problems are going to be,” said Elizabeth M. Byrnes, an associate professor at Cummings School, who studies the effects of opioids in rats in her neuroscience lab to provide valuable data for clinicians. “Animal models, if done correctly, can help us figure out strategies to address issues before they develop.”

Illustration: Andy Martin

The problem is that many of the animal studies done to date may not translate well enough to human biology and physiology, according to a recent analysis by Byrnes and Fair Vassoler, a research assistant professor at Cummings School. That’s why they’re designing experiments that more closely mimic real-world conditions, while isolating biological effects from the knotty socioeconomic issues complicating addiction. Their recent findings suggest even small exposures to the opioids can have far-ranging impacts on the next generation. And these rigorous animal models could lead the way to new treatments for the most vulnerable patient populations.

In a 2017 article in Frontiers in Neuroendocrinology, Byrnes and Vassoler reviewed 178 animal studies of prenatal opioid exposure published over the last four decades. One problem was that, in most of the research models, rodents were given drugs starting at the first day of pregnancy or for just a few days during their pregnancy. “That’s not very translational,” Vassoler said. “Women don’t typically wait until pregnancy to start abusing opioids. And what we know about addiction is that chronic exposure and sustained abuse lead to adaptations and physiological changes that can really affect the body going forward.”

There’s more that doesn’t translate: Many studies claim to represent full-pregnancy and perinatal exposure to opioids, when rat and human gestation periods just aren’t comparable. And the vast majority of the animal opioid models used morphine, instead of the more commonly misused substance oxycodone or therapy drugs such as methadone. “Ideally, we need these models to test different replacement therapies so we can determine their effects in offspring,” Vassoler said. For example, she suspects that methadone may be problematic because it seems to create strong withdrawal symptoms in babies.

“We can’t afford to wait until all these kids hit first grade, middle school, and adulthood to learn what the problems are going to be.”

Cummings School researchers are working on a rodent model of voluntary opioid intake that more closely simulates real-world maternal drug use. In the first rodent study to feature intravenous self-administration of an opioid, rats were trained to choose if they wanted a dose of oxycodone. “The rats manage their own drug use by pressing a button when they want an infusion,” Vassoler said, noting that this simulates a person choosing to take drugs.

The rats had access to the oxycodone for at least three weeks before mating—a long period in the life of a rodent—as well as during pregnancy, followed by a withdrawal period after birth. “This allows us to see how the physiological changes that occur during pregnancy affect their desire to take more or less drugs, absent all those societal restraints that tell human mothers what to do,” Vassoler said. The researchers then examined the animals’ offspring-maternal interactions to assess if drug exposure affects communication and care, and if the pups develop symptoms of withdrawal.

Overall, the study, presented at the November 2017 annual meeting of the Society for Neuroscience, found that even limited voluntary intake of oxycodone before and during pregnancy can disrupt maternal care, as well as cause changes in proteins critical for brain development in offspring. A higher cumulative intake of oxycodone by the mother was also correlated with lower body weights in her offspring, as well as fewer calls from the pups requesting attention from their mother.

Going forward, Cummings School researchers hope to use this new model to test therapeutic options for pregnant women in treatment for opioid abuse. They are particularly interested in determining the safest and most effective combinations of medications. “Most animal studies focus on just one drug. But many of these women in recovery are also struggling with mental health challenges, such as depression, mood disorders, PTSD, or other issues,” Byrnes said. “Clinicians may need to put these mothers on opioid maintenance therapy, as well as on a mood stabilizer or antidepressant.”

The researchers also want their work to provide evidence for policy changes that would better support women in recovery and their families. “But the only way to do that,” Byrnes said, “is if there is good science available.”

 

Testing A New Addiction Therapy

Cummings School Research Assistant Professor Fair Vassoler is working with Weinberg Medical Physics, a Maryland-based medical-device incubator, to study a new way to potentially curb opioid cravings. In March, the project received a $230,000 seed grant from the National Institute of Health’s National Institute on Drug Abuse.

The work will test if a new kind of deep-brain-stimulation can reduce drug-seeking behaviors. Traditional deep-brain stimulation uses electrodes implanted in the brain to trigger different kinds of neurological activity. The FDA-approved procedure has successfully treated movement disorders, such as Parkinson’s disease, with few serious side effects. While a graduate student researcher at University of Pennsylvania, Vassoler conducted research indicating that the treatment reduced cocaine-seeking behavior in rats, a model of human relapse.

Now, Weinberg Medical Physics has developed a minimally invasive version of deep-brain stimulation, using an MRI machine to guide magnetic nanoparticles—each smaller than a red blood cell—up through the nasal cavity and into the reward center of the brain. With the new technology, “human patients in recovery for addiction would wear a hat that signals the little particles to wiggle, stimulating neurons that help reduce cravings whenever they recur,” Vassoler said. “We will be trying it in rats in hopes of it becoming commercially available for human patients in recovery.”

Top Stories

A Revolution in Grafton

Over 40 years, Cummings School has built itself into an international leader in veterinary education, expert clinical care, and interdisciplinary research.

Editor's Picks

A Mastiff Issue in China

A conservation medicine alum addresses the problem of free-ranging dogs on the Tibetan plateau.

On the Road with the Goat Doc

After she had trouble finding care for her own dairy goats, Cara Sammons-Shepard, V16, decided to become a traveling veterinarian herself.

Birth of the Veterinary School

Over 40 years, Cummings School has become an international leader in veterinary medicine. And all it took was buying nearly 600 acres for a dollar, palpating police horses, and performing the occasional surgery by penlight.